Leiden, The Netherlands, September 3rd, 2024 - Eyesiu Medicines BV, a Leiden Bio Science Park company that creates innovative therapeutics and nutraceuticals based on advanced delivery technology, received the news today that on August 26th 2024 the Korean Intellectual Property Office has granted Eyesiu a patent entitled “Pegylated lipid nanoparticle with bioactive lipophilic compound” ( No. KR20187006989 ). South Korea is the sixth country in a row - following USA, Taiwan, Russia, Japan and India - to provide a granted patent to Eyesiu for its inventions described in the patent application ““Pegylated lipid nanoparticle with bioactive lipophilic compound”. Now the application is only still pending in the EU and China. The Korean Intellectual Property Office granted claims for the solvent-free and serum-stable lipid (nano)particles comprising two neutral phospholipids (DSPE and HSPC) and at least one of palmitoylethanolamide (PEA), an endocannabinoid from the group of acylethanolamides, and a macrolide (such as CsA, tacrolimus or sirolimus), wherein the lipid particle has a surface comprising a water soluble polymer (PEG). Eyesiu’s therapeutics and nutraceuticals Eyesiu has developed therapeutics, in pre-clinical stage, targeting a wide range of indications in neurology, ophthalmology, dermatology and pulmonology. The company has also developed nutraceuticals (food supplements) that support its users to maintain pain-free and healthier brain, eyes, lungs, skin and/or hair: the first one is a spray bottle with PEA, comprising a lipid-based sublingual, skin and mouth spray formulation for convenient, effective, fast and sustained delivery, and is for sale through Eyesiu’s health care division (Eyesiu Care) via www.PEArlboost.com About Eyesiu Medicines BV See www.eyesiu.com for more information, and to see how you can join and own shares in the company, or close a product partnership . For further information, please contact Eyesiu Medicines BV | Pieter J. Gaillard | info@eyesiu.com

Ons lichaam is in staat zichzelf te herstellen. Hippocrates (460–377 v.Chr.) noemde dit ‘physis’, het natuurlijk aanwezige zelfgenezend vermogen. In de meeste gevallen kan je zelfstandig goed genezen van allerlei interne en externe prikkels die ons lichaam constant onder vuur nemen. Zo zijn we langdurig in staat om effectief de brandjes te blussen die veroorzaakt kunnen worden door de meest uiteenlopende trauma’s, infecties, allergenen, straling, chemicaliën, mutaties, metabolieten, ziektes, en ook door de (over)actieve ontstekingsfactoren uit ons eigen afweersysteem. Een gezonde voeding en leefstijl helpt daarbij om een sterk, gebalanceerd en veerkrachtig afweersysteem op te bouwen. Door langdurig lichaamseigen blusstofjes te verbruiken kunnen toch verlaagde waarden daarvan in het lichaam ontstaan, waardoor brandjes kunnen blijven voortduren. Dan is gerichte suppletie met voedingssupplementen (zoals met PEA) de oplossing, hoe sneller hoe beter.

Dit blog gaat over medicijnverslaving, met name over hoe pijnlijk moeilijk het is om daarvan af te kicken, mijn persoonlijke verbazing over de medische adviezen om van deze verslaving af te komen, en [dus] mijn motivatie om bij te willen dragen aan het anderen helpen slagen met overwinnen van deze pijn. En wat blijkt: er is nog een wereld te winnen, en er is gelukkig ook houvast en hoop te vinden in reeds beschikbare mogelijkheden die tot nu toe - ik vind onterecht - onvoldoende benut zijn gebleven.

- 23 mei 2020 - Gerichte ondersteuning van gezonde voeding en leefstijl. Zo lang het virus onder ons is zal COVID-19 de maatschappij in de greep houden, en daarbij angst en verdeeldheid blijven zaaien. Hoe lang we in die situatie zullen blijven zal in grote mate afhangen van de wereldwijde beschikbaarheid van een nieuw te ontwikkelen, veilig en effectief vaccin en/of therapie tegen het virus en de gevolgen ervan op het lichaam. Er zijn inmiddels een heel aantal vaccin-kandidaten in de race, en er worden veel nieuwe therapieën getest (I). Ook is er weer meer aandacht voor het versterken van de weerstand van ons lichaam tegen infecties en ziektes, met name door middel van gezonde voeding en leefstijlinterventies (II). De rol van voedingssupplementen om mee te strijden tegen COVID-19 komt hier nu ook aan de orde (III).

- May 12, 2020 - Soothing vascular inflammation whilst eradicating the virus. As long as the COVID-19 disease is amongst us, and as long as there is no safe and effective vaccine, or affordable and widely applicable anti-viral drug available to all people around the globe, our world will not return to as it was before. Meanwhile the virus will continue to cause (hyper)inflammatory responses in the blood, the vasculature and thereby have major impact on the functioning of all major organs, foremost in lungs, heart, skin and brain. These responses were so far found to be most detrimental to people of older age and with underlying vascular pathologies. Yet, as long as this pandemic continues, all of us at least stand at risk of developing the perhaps milder and more manageable vascular inflammatory and thrombotic conditions, albeit with sometimes severe complications as a result (like cerebrovascular accidents / stroke).

Na jaren van zorgvuldig opbouwen is de dag gekomen om Eyesiu (lees “I see you”, oftewel ”ik zie je”; wat betekent “ik heb respect voor je”) open te stellen voor iedereen om een aandeel in het succes te kunnen nemen. Iedereen is welkom die geloof heeft in de missie en visie van de onderneming, en die vertrouwen heeft in de kunde en ervaring van de betrokken professionals. Zo help je om betaalbare innovatieve producten sneller beschikbaar te maken voor consumenten en patiënten die noodzaak of behoefte hebben aan gezondere hersenen, ogen, huid en longen. Kom erbij en doe mee via https://www.eyevestor.com/members/eyeventures/NL_YCU

Is het lastig om pillen, capsules of vloeistoffen door te slikken? Zorgt moeite met slikken voor sociale en gezondheidsproblemen, en voor het uitstellen, weigeren of vergeten van het dagelijks innemen van geneesmiddelen of belangrijke vitamines en voedingssupplementen welke kunnen helpen het lichaam fit, sterk, pijnvrij en veerkrachtig te houden? Is meer controle gewenst over de hoeveelheid of portie van een pil of capsule die gebruikt wordt? En wil je wél snelle afgifte en opname bereiken? Dan is een toediening van de vitamines en voedingssupplementen met behulp van een handig spray flesje de ideale oplossing.

Leiden, 17 september 2022 - Tijdens de Leidse Nacht van Ontdekkingen kan je bij Eyesiu de Pikante Peper Smaakt Test komen doen. Zo ga je ontdekken welke pittigheid score jij geeft aan een shotje Virgin Bloody Mary (tomatensap met Tabasco). Hierdoor ontdek je wat activatie van het TRPV1 kanaal door de capsaïcine uit rode pepers bij jou in je mond doet op een schaal van 0 (“niets merkbaar”) tot 5 (“ik wil geen volgende meer testen”). En er zijn testflesjes van Eyesiu’s mondspray met het voedingssupplement PEArlboost++, waarvan we weten dat het ingrediënt palmitoylethanolamide (PEA) de gevoeligheid van het TRPV1 kanaal kan beïnvloeden. Dit mag je zelf testen. Zo leer je ter plekke hoe je kan onderzoeken of remming van het TRPV1 kanaal bij jou misschien een verandering van de smaaksensatie van pikante peper kan geven! Who Knows!

Op het Leids Goeds Festival van 11 mei 2022, kan je bij Eyesiu de Pikante Peper Smaak Test komen doen, en zo uitvinden welke pittigheid score jij aan een Virgin Bloody Mary geeft. Vervolgens mag je dan testen wat jouw gratis mondspray TESTFLESJE met het voeddingssupplement PEArlboost bij jou doet op je Pikante Peper Smaak Sensatie.

Het Leidsch Dagblad heeft een serie verhalen over het Leiden Bio Science Park, mede mogelijk gemaakt door het Leids Mediafonds. Het Bio Science Park is de economische motor van Leiden, de kurk waar de stad op drijft. Honderden bedrijven werken er aan de wereld van morgen. Maar wat doen ze precies? De komende maanden duikt het Leidsch Dagblad in de wereld van de biotech in de regio. Deze keer: Eyesiu, een bedrijf dat een parelmoerspray op basis van lipide microdeeltjes op de markt brengt die ontstekingsremmend werkt. En de ontstekingsremmers in de lipide nanodeeltjes zijn in ontwikkeling als geneesmiddel. Het stuk is ook te vinden op: https://www.leidschdagblad.nl/cnt/dmf20220204_24742831. Journalist & ondernemer Martijn de Meulder interviewde oprichter en directeur van Eyesiu, Pieter J. Gaillard, over zijn professionele leven, en wat inmiddels zijn levenswerk is geworden: het passeren van de bloed-hersenbarrière.

“The 2021 Nobel Prize in Physiology or Medicine is awarded to David Julius and Ardem Patapoutian for their discoveries of thermal and mechanical transducers”, as cited from the Scientific Background on www.nobelprize.org; “David Julius wished to identify the cellular target of capsaicin, the pungent ingredient of chili peppers, as he believed this could provide fundamental insights into mechanisms of pain. He used a cDNA library from sensory neurons in a functional screen to look for a gene that could confer capsaicin sensitivity to cells that were normally unresponsive. The screen identified a cDNA encoding a novel ion channel (now called TRPV1) belonging to the family of transient receptor potential ion channels. Importantly, TRPV1 was shown to be activated by temperatures perceived as painful.” Eyesiu congratulates the laureates and welcomes the acknowledgement of these important scientific discoveries

€1,3M funding to CONNECT the Blood-Brain Barrier to Cerebral Organoids (18957). The Blood-Brain Barrier (BBB) protects the brain from unwanted compounds also hampering the delivery of therapeutics into the brain. Available animal models do not fully reflect disease conditions as seen in patients, making drug discovery a challenge and creating a need for models that predict all aspects of the route and effects of a drug upon administration.

On February 1st 2021, a Nature Machine Intelligence publication listed 10 compounds as potential drugs to be repurposed for COVID-19 treatment. It happens to be that 5 of them are specifically captured in Eyesiu’s innovative solvent-free and serum-stable lipid nanoparticles, including CsA, Voclosporin, Valspodar, Alisporivir and NIM811. And this confirmation for CsA follows earlier clinical reports in the Lancet and Journal of Internal Medicines that CsA has specific therapeutic use in patients with COVID-19.

Eyesiu Medicines BV, a Leiden Bio Science Park company that creates innovative therapeutics and nutraceuticals based on advanced delivery technology, is pleased that today it was announced by Health~Holland and Leiden University that our public-private partnership was awarded €1 million for Corona Research, aimed at Predicting and Preventing COVID-19. With the new collaboration project, the consortium partners hope to improve patient care for intensive care patients, the elderly and at-risk groups. With the models and specific metabolomic fingerprints, they will also be able to test the effect of existing and new drugs or, for example, to optimise patients' diets and dietary supplements, which is the core expertise and contribution of Eyesiu Medicines BV in this partnership. This prestigious project is a collaboration of expert partners in this field, joined together by Thomas Hankemeier, professor Analytical biosciences at Leiden University and leader of the consortium

Het Leidsch Dagblad heeft in het SLIM katern van vrijdag 16/10/2020 een artikel geplaatst over de schadelijke effecten van Corona op de hersenen. SLIM is een gedeelde wetenschapsbijlage van het Noord-Hollands Dagblad, Haarlems Dagblad, De Gooi- en Eemlander en het Leidsch Dagblad. Freelance journalist Anika van de Wijngaard interviewde oprichter en directeur van Eyesiu, Pieter J. Gaillard, over wat het coronavirus allemaal aan kan richten in de hersenen. Vanuit dit eerste gesprek is het stuk uiteindelijk vormgegeven met bijdrages van medisch specialisten uit het LUMC en Radboud UMC over wat het virus doet met de doorlaatbaarheid van de beschermende barrière in de bloedvaten in het brein, de vorming van bloedstolsels, en de overvloed van ontstekingsfactoren. En waar er met bestaande medicijnen en slimme voedingssupplementen een positieve bijdrage gegeven kan worden op deze processen. Het volledige artikel is hieronder weergegeven.

PEA (palmitoylethanolamide): today’s available, long-forgotten, body-own “vitamin”, that was demonstrated to be superior in helping the body to manage respiratory tract infections / acute respiratory diseases (ARD). Orally taken capsules of PEA were proven highly beneficial already in the 1970s, tested on >2,700 factory workers, soldiers and school children, in 5 randomised, double-blinded, placebo-controlled clinical trials, while no side effects were registered after several years of clinical testing of PEA in military and civilian communities. Now, the question is, would PEA also help cope with the new #coronavirus #COVID19? According to its known biological function and impressive data presented in the publications, summarised in the table below, the answer to this question is likely positive, and obvious to try.

Leiden, The Netherlands, August 24th, 2023 - Eyesiu Medicines BV, a Leiden Bio Science Park company that creates innovative therapeutics and nutraceuticals based on advanced delivery technology, received the news today that on July 28th 2023 the Patent Office of the Government of India has granted Eyesiu a patent entitled “Pegylated lipid nanoparticle with bioactive lipophilic compound” ( No. 436132 ). India is the fifth country in a row - following US, Taiwan, Russia and Japan - to provide a granted patent to Eyesiu for its inventions described in the patent application ““Pegylated lipid nanoparticle with bioactive lipophilic compound”. Now the application is only still pending in the EU, China and South Korea. The Patent Office of India granted claims for the solvent-free and serum-stable (nano)particles comprising two or more select neutral phospholipids and at least one of an acylethanolamide (such as the endocannabinoids 2-arachidonoylglycerol (2-AG), arachidonoylethanolamide (AEA or anandamide), oleoylethanolamide (OAE), or palmitoylethanolamide (PEA)) and a macrolide (such as tacrolimus, sirolimus or cyclosporine A), wherein the nanoparticle of 150 nm or less has a surface comprising a water soluble polymer (such as PEG). Eyesiu’s therapeutics and nutraceuticals Eyesiu has developed therapeutics, in pre-clinical stage, targeting a wide range of indications in neurology, ophthalmology, dermatology and pulmonology. The company has also developed nutraceuticals (food supplements) that support its users to maintain pain-free and healthier brain, eyes, lungs, skin and/or hair: the first one is a spray bottle with PEA, comprising a lipid-based sublingual, skin and mouth spray formulation for convenient, effective, fast and sustained delivery, and is for sale through Eyesiu’s health care division (Eyesiu Care) via www.PEArlboost.com About Eyesiu Medicines BV See www.eyesiu.com for more information, and to see how you can join and own shares in the company, or close a product partnership . For further information, please contact Eyesiu Medicines BV | Pieter J. Gaillard | info@eyesiu.com

A patent was granted in Japan for Eyesiu’s PEArlboost and Cyslosporine A (CsA) lipid particle formulas. The granted claims cover an innovative PEGylated lipid particle spray that boosts the fast and sustained delivery of for instance the effective food supplement palmitoylethanolamide (PEA) and immunosuppressive CsA, which is likely the best compound known to date to reduce mortality in COVID-19. Also included in this set of allowed claims are all other related endocannabinoids from the group of acylethanolamides, such as 2-arachidonoylglycerol (2-AG), arachidonoylethanolamide (AEA or anandamide) and oleoylethanolamide (OAE), and other macrolides such as tacrolimus and sirolimus.

PEArlboost, Eyesiu’s innovative PEGylated lipid particle spray formula that boosts the fast and sustained delivery of the effective food supplement palmitoylethanolamide (PEA), has now also been granted a full composition of matter and use patent by the USPTO. Also included in this expanded set of allowed claims are all other related endocannabinoids from the group of acylethanolamides, such as 2-arachidonoylglycerol (2-AG), arachidonoylethanolamide (AEA or anandamide) and oleoylethanolamide (OAE).

After US and Taiwan, Russia allows Eyesiu's patent claims on novel formulations of palmitoylethanolamide (PEA) and Cyclosporine A (CsA), which is likely the best compound known to date to reduce mortality in COVID-19. Leiden, The Netherlands, August 23rd, 2020 - Eyesiu Medicines BV, a Leiden Bio Science Park company that creates innovative therapeutics and nutraceuticals based on advanced delivery technology, received “Decision to Grant” letter from the Federal Service for Intellectual Property (ROSPATENT) of Russia for its proprietary formulation and medical use patent application “Pegylated lipid nanoparticle with bioactive lipophilic compound” (2018108203/04(012689)).

Leiden, The Netherlands, August 11th, 2020 - Eyesiu Medicines BV, a Leiden Bio Science Park company that creates innovative therapeutics and nutraceuticals based on advanced delivery technology, received “Notice of Allowance” from the Intellectual Property Office of the Ministry of Economic Affairs of Taiwan for its proprietary formulation and medical use patent application “Pegylated lipid nanoparticle with bioactive lipophilic compound” ( TW201705973A; 105125583; No. I709410 ). The Leiden Bio Science Park company Eyesiu Medicines BV received “Notice of Allowance” for its patent application ““Pegylated lipid nanoparticle with bioactive lipophilic compound” ( TW201705973A; 105125583; No. I709410 ) from the Intellectual Property Office of the Ministry of Economic Affairs of Taiwan. In January 7th, the patent was granted by the US Patent and Trademark Office (USPTO; US15/751,170 ), while the application is pending in the EU, Russia, China, South Korea, Japan and India. The allowable claims for the nanoparticles comprise one or more phospholipids and at least one of an acylethanolamide (such as the endocannabinoids 2-arachidonoylglycerol (2-AG), arachidonoylethanolamide (AEA or anandamide), oleoylethanolamide (OAE), or palmitoylethanolamide (PEA)) and a macrolide (such as tacrolimus, sirolimus or cyclosporine A), wherein the nanoparticle has a surface comprising a water soluble polymer (such as PEG). “Being rewarded with an issued patent by Taiwan and the US for the core of our invention is very gratifying and a validation of Eyesiu’s series of related therapeutics and nutraceutical products in development and available on the market”, comments Dr. Pieter J. Gaillard, founder and CEO of Eyesiu. “This second allowance of Eyesiu’s patent application by the Taiwanese Intellectual Property Office of the Ministry of Economic Affairs with broad and commercially relevant claims further supports our belief that the technology will also obtain similar product protection in the other geographies where the application is currently pending”, Gaillard adds. Eyesiu’s therapeutics and nutraceuticals Eyesiu has developed therapeutics, in pre-clinical stage, targeting a wide range of indications in neurology, ophthalmology, dermatology and pulmonology. The company has also developed nutraceuticals (food supplements) that support its users to maintain pain-free and healthier brain, eyes, lungs, skin and/or hair: the first one is a spray bottle with PEA, comprising a lipid-based sublingual, skin and mouth spray formulation for convenient, effective, fast and sustained delivery, and is for sale through Eyesiu’s health care division (Eyesiu Care) via www.PEArlboost.com About Eyesiu Medicines BV and Eyesiu Care For more information see www.eyesiu-medicines.com and www.eyesiu-care.com For further information, please contact Eyesiu Medicines BV | Pieter J. Gaillard | info@eyesiu.com